🇺🇸 FDA
Company

Kiniksa

Kiniksa Pharmaceuticals International, plc

KNSA pharma USA

Quick answer

Kiniksa is a pharma company (KNSA) headquartered in LONDON, USA with 12 tracked pipeline programs.

Pipeline (12)

project

KPL-387

Pericarditis

Phase 3 · small_molecule · active

1 trials project

Rilonacept

Recurrent Pericarditis

Phase 3 · small_molecule · completed

1 trials project

mavrilimumab

COVID

Phase 3 · small_molecule · completed

1 trials project

Abiprubart

Sjögrens Disease

Phase 2 · small_molecule · terminated

1 trials project

KPL-387

Recurrent Pericarditis

Phase 2 · small_molecule · active

1 trials project

KPL-404

Arthritis, Rheumatoid

Phase 2 · small_molecule · completed

1 trials project

KPL-716

Chronic Idiopathic Urticaria

Phase 2 · small_molecule · completed

1 trials project

KPL-914

Recurrent Pericarditis

Phase 2 · small_molecule · completed

1 trials project

Mavrilimumab

COVID-19

Phase 2 · small_molecule · completed

3 trials project

Vixarelimab

Prurigo Nodularis

Phase 2 · small_molecule · completed

1 trials project

mavrilimumab

Giant Cell Arteritis

Phase 2 · other · completed

1 trials project

KPL-404

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials

Drugs (1)

drug

rilonacept

ARCALYST

Patents (8)

patent

US 12234294

Pharmaceutical composition of a humanized anti-CD40 antibody

Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12122837

Oncostatin M receptor antigen binding proteins

Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11141479

Stable anti-OSMR antibody formulation

Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10493149

Stable anti-OSMR antibody formulation

Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10421813

Oncostatin M receptor antigen binding proteins

Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10391170

Stable anti-OSMR antibody formulation

Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9738721

Oncostatin M receptor antigen binding proteins

Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9663571

Oncostatin M receptor antigen binding proteins

Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)